PGP and cancer: Bearing in mind that sorafenib and probably morphine belong to the P-gp substrates, and sorafenib is also a P-gp inhibitor [10,11,12], the combined use of these drugs may alter their pharmacokinetics, and finally, the safety and efficacy of the cancer therapy.